Bendroflumethiazide D7
| Product Name | Bendroflumethiazide D7 |
|---|---|
| Alternate Names | Bendroflumethiazide Stable Isotopes, Stable Isotopes of Bendroflumethiazide |
| CAT No. | CS-CX-00565 |
| CAS No. | 73-48-3 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Bendroflumethiazide |
| Therapeutic | Anti-Hypertensives |
| Smileys | O=[S]1(C2=CC([S](N)(=O)=O)=C(C(F)(F)F)C=C2NC(C([2H])([2H])C(C([2H])=C3[2H])=C(C([2H])=C3[2H])[2H])N1)=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Bendroflumethiazide D7 is a deuterated analog of bendroflumethiazide, a thiazide diuretic drug used for the treatment of hypertension, congestive heart failure, and edema. Bendroflumethiazide D7 is a labeled compound that contains seven deuterium atoms, which makes it suitable for use as an internal standard in mass spectrometry analysis.
The mechanism of action of bendroflumethiazide D7 is similar to that of other thiazide diuretics. It works by inhibiting the sodium-chloride co-transporter in the distal convoluted tubule of the kidney, leading to increased excretion of sodium, chloride, and water. This results in a decrease in blood volume and a reduction in blood pressure.
Bendroflumethiazide D7 is administered orally and is rapidly absorbed from the gastrointestinal tract. The drug is metabolized in the liver and excreted primarily in the urine. The half-life of bendroflumethiazide D7 is approximately 3-4 hours, and the drug reaches its peak plasma concentration within 2-4 hours after administration.
Bendroflumethiazide D7 is a useful tool for pharmacokinetic and pharmacodynamic studies of bendroflumethiazide. It is also used in research to study the metabolism and excretion of the drug. However, it must be handled with care due to its potential toxicity and should only be used by trained professionals in a laboratory setting.
Get an Instant Quote
Related Compounds
N-Nitroso rac Bendroflumethiazide-D5 | Bendroflumethiazide D5 |